Why Some Doctors Say Stem Cells Don’t Work — Why Some Use

Why doctors say stem cells don’t work in guideline-based medicine

Patients exploring Stem Cell therapy frequently encounter a stark divide in medical opinion. Some physicians strongly discourage it, while others incorporate it into daily clinical practice. This disagreement is often misinterpreted as a conflict between “believers” and “skeptics,” but in reality, it reflects how modern medicine evaluates evidence and defines effectiveness.

When doctors say stem cells “don’t work,” they are usually speaking from the perspective of guideline-based medicine. In this framework, treatments are considered effective only after meeting strict criteria, including large randomized controlled trials, standardized dosing protocols, fixed indications, and long-term outcome data. For most Stem Cell therapies, especially those involving musculoskeletal and neurological conditions, this level of standardization has not yet been achieved.

Importantly, this position does not imply that stem cells lack biological activity. Rather, it reflects caution in the absence of universally accepted protocols and regulatory approval for specific disease indications.

Why regenerative medicine does not behave like conventional drug therapy

A major source of skepticism arises from comparing stem cell therapy to pharmaceutical drugs. Conventional medications follow a linear model: a defined molecule targets a specific biological pathway, producing a relatively predictable response across populations. This model aligns well with regulatory systems and clinical guidelines.

Stem cell therapy functions differently. Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs)do not act as replacement parts or permanent implants. Instead, they exert their effects through paracrine signaling—releasing bioactive molecules such as cytokines, growth factors, and extracellular vesicles that influence inflammation, immune regulation, angiogenesis, and tissue repair pathways.

These effects are highly context-dependent. Disease stage, inflammatory burden, metabolic health, mechanical stress, and immune status all influence outcomes. As a result, responses vary between patients, which challenges traditional expectations of reproducibility but aligns with known principles of regenerative biology.

Why “not FDA-approved” does not mean biologically ineffective

Another common reason doctors dismiss Stem Cell therapy is the lack of approval by the U.S. Food and Drug Administration for most stem cell indications. FDA approval requires a fixed formulation, fixed dose, and fixed indication—criteria that are difficult to apply to living cellular products that interact dynamically with individual patients.

This regulatory reality has led many physicians to equate “not FDA-approved” with “does not work,” even though these concepts are not equivalent. Numerous medical procedures and biologic therapies entered clinical use before formal guideline endorsement, particularly in fields such as orthopedics and sports medicine.

Stem cells currently occupy a similar transitional phase, where biological plausibility and early-to-moderate clinical evidence exist, but universal standardization has not yet been achieved.

Why some doctors use stem cells daily in clinical practice

Physicians who regularly use stem cell therapy tend to work in specialties where inflammation and degeneration play central roles. Orthopedic surgeons managing knee osteoarthritis, sports medicine physicians treating tendon degeneration, and neurologists addressing neuroinflammatory conditions often observe consistent patterns when UC-MSCs are used appropriately.

These clinicians do not view stem cells as curative. Instead, they use them as biologic modulators—to reduce inflammation, support tissue repair pathways, and improve function. In carefully selected patients, they frequently observe meaningful reductions in pain, improved mobility, and enhanced quality of life, particularly in early-to-moderate disease stages.

Crucially, these doctors understand that stem cells do not permanently remain in the body. Most MSCs are active for days to weeks, while downstream biological effects may persist for months to years, depending on the condition and patient-specific factors.

Why patient selection determines success or failure

One of the strongest drivers of disagreement among doctors is patient selection. Stem cell therapy performs best when viable tissue remains and inflammation is a primary contributor to symptoms. In knee osteoarthritis, for example, outcomes are more favorable in mild-to-moderate disease than in advanced bone-on-bone arthritis.

When stem cells are applied to end-stage disease characterized by complete tissue loss or mechanical instability, results are understandably limited. Physicians who frequently encounter such cases may conclude that stem cells “don’t work,” when in reality the biology was no longer responsive.

This distinction highlights why regenerative therapies require careful screening and realistic expectation-setting rather than broad, one-size-fits-all application.

Why stem cell therapy results are time-dependent, not permanent

Another reason some doctors reject Stem Cell therapy is the misconception that effective treatments must produce permanent results. UC-MSCs do not permanently engraft or continuously regenerate tissue. Their role is to modulate the biological environment, reduce inflammation, and activate repair pathways.

Over time, aging, mechanical stress, metabolic dysfunction, and lifestyle factors can re-establish the conditions that led to degeneration. This time-dependent nature does not represent treatment failure; it reflects how regenerative biology operates. Repeat or maintenance treatments are often discussed in research protocols for chronic conditions, similar to how medications are taken continuously rather than once.

Why safety and regulation influence physician acceptance

Safety considerations also shape medical opinions. Ethical concerns arise when Stem Cell therapies are marketed aggressively without adequate screening, laboratory standards, or physician oversight. In Thailand, Stem Cell therapies fall under Thai FDA regulatory frameworks, with emphasis on laboratory quality, sterility, and physician-led care.

For stem cell applications, sourcing UC-MSCs from GMP-certified laboratories is critical to ensuring cell viability, consistency, and safety. Clinics adhering to these standards align more closely with international ethical expectations, whereas poorly regulated environments contribute to skepticism across the medical community.

Why disagreement reflects different thresholds for evidence, not denial of science

Evidence-based medicine evolves gradually. Many accepted treatments today were once considered experimental or controversial. Stem cell therapy currently resides in an intermediate stage, supported by biological rationale and growing clinical data, but lacking universal standardization.

Some physicians choose to wait for guidelines to catch up. Others, guided by emerging evidence and clinical experience, apply stem cell therapy cautiously and selectively. Both positions reflect legitimate medical reasoning rather than ideological opposition

What patients should understand before making decisions

Stem ฉell therapy is not a cure, does not halt aging, and does not replace surgery in advanced disease. What it can do—when used responsibly—is reduce inflammation, support tissue repair mechanisms, improve function, and slow disease progression for a meaningful period of time.

Patients who understand these limitations tend to be far more satisfied with outcomes than those expecting permanent or immediate transformation.

How to interpret conflicting medical opinions on stem cells

When some doctors say stem cells don’t work, they usually mean the therapy has not yet reached guideline-level standardization. When others use stem cells daily, they mean that in carefully selected patients, under controlled conditions, they observe consistent clinical benefit. Both statements can be true simultaneously.

About EDNA Wellness

EDNA Wellness is a private Stem Cell Clinic and Regenerative Medicine Center in Bangkok, Thailand, specializing in Umbilical cord–derived Mesenchymal Stem Cells (UC-MSCs) for knee osteoarthritis and joint pain, stroke and other neuro-related conditions, and stem cell IV infusions for longevity and healthy aging. All treatments are doctor-designed and performed in a sterile clinical setting

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

Website: www.ednawellness.com

References

MENU